バージニアにおける非小細胞肺癌の臨床試験
バージニア内の拠点で、非小細胞肺癌に関する137件の研究が参加者を募集しています。
バージニア内の都市
- Arlington104件の研究
- Richmond25件の研究
- Charlottesville21件の研究
- Alexandria11件の研究
- Roanoke8件の研究
- Norfolk7件の研究
- Winchester6件の研究
- Fredericksburg5件の研究
- Lynchburg4件の研究
公式研究テキスト（英語）
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Ballad Health Cancer Care - Bristol, Bristol
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Centra Alan B Pearson Regional Cancer Center, Lynchburg
- 他7件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT04267848A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Virginia Cancer Specialists ( Site 0167), Fairfax
- Virginia Oncology Associates (VOA) ( Site 8101), Norfolk
- VCU Health Adult Outpatient Pavillion ( Site 0193), Richmond
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06623422The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Virginia Cancer Specialists, Fairfax
被験者募集中第1/2相
12歳以上 · 全性別 · 2026/10/02更新 · NCT04585750A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
- Blue Ridge Cancer Center, Blacksburg
- Virginia Cancer Specialists, PC, Fairfax
- Shenandoah Oncology P.C., Winchester
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/10/02更新 · NCT07365319A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- Inova Schar Cancer Institute, Fairfax
- NEXT Virginia, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06270706Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #66, Charlottesville
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/01更新 · NCT05176483A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
- Hematology Oncology Associates of Fredericksburg ( Site 3275), Fredericksburg
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07513376A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)
- Virginia Cancer Specialists ( Site 0114), Fairfax
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07554339A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- Hematology Oncology Associates of Fredericksburg ( Site 9550), Fredericksburg
- Blue Ridge Cancer Care ( Site 0144), Roanoke
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07190248Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Hematology Oncology Associates of Fredericksburg Inc, Fredericksburg
- Centra Alan B Pearson Regional Cancer Center, Lynchburg
- Virginia Cancer Institute, Richmond
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06498635A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
- ALX Center 2, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07085091A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Blue Ridge Cancer Care, Christiansburg
- Virginia Oncology Associates, Norfolk
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07361497A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors
- Site 04, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07814248A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Local Institution - 0337, Richmond
- Shenandoah Oncology, P.C., Winchester
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07361510A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
- University of Virginia, Charlottesville
- Virginia Cancer Specialists, Fairfax
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07659782Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
- Virginia Cancer Specialists, Fairfax
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT06765109Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Virgnia Cancer Specialists /ID# 269633, Leesburg
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06772623Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
- Virginia Cancer Specialists, Fairfax
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/29更新 · NCT06881784A Study of PHN-012 in Patients With Advanced Solid Tumors
- PHN-012-001 Site, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/29更新 · NCT07127874A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Oncology & Hematology Associates of Southwest Virginia,Inc.DBA Blue Ridge Cancer Care, Blacksburg
- Oncology & Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer care| Emmett Medical & Surgical Center, Low Moor
- VCU Emergency Center at New Kent, Quinton
- 他12件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07144280A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Virginia Cancer Specialists, Fairfax
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT05498428Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- UVA Comprehensive Cancer Center, Charlottesville
- UVA Health Fontaine Research Park, Charlottesville
- University of Virginia, Charlottesville
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07222566A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
- Virginia Cancer Specialists, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07227025A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Virginia Cancer Specialists, Fairfax
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT06667076Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
- VCU Medical Center Gateway Building, Richmond
- Virginia Commonwealth University, Richmond
- VCU Health Stony Point, Richmond
- 他4件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07227298Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- University of Virginia Health System, Charlottesville
- VCU Health Adult Outpatient Pavillion, Richmond
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06890598Pan-tumor MRD Study
- Virginia Cancer Institute, Richmond
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/24更新 · NCT06605404Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- University of Virginia Cancer Center, Charlottesville
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT03191149Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Research Site, Fort Belvoir
- Research Site, Leesburg
- Research Site, Midlothian
- 他1件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/23更新 · NCT06357533A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
- Virginia Cancer Specialists PC, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/23更新 · NCT07140016Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer
- Research Site, Fairfax
被験者募集中第2相
18歳〜95歳 · 全性別 · 2026/09/23更新 · NCT05061550Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- Virginia Cancer Specialists - Arlington, Arlington
- Virginia Cancer Specialists, Fairfax
- VCU Massey Cancer Center, Richmond
- 他1件
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06712316Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- NEXT Oncology Virginia, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Virginia Cancer Specialists - Fairfax /ID# 272004, Fairfax
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06568939A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
- Inova Schar Cancer Institute Clinical Trials, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07488676Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- University of Virginia Health System, Charlottesville
- Virginia Commonwealth University (Vcu), Richmond
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07100080Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Virginia Cancer Specialists, Fairfax
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/21更新 · NCT05983432A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
- Next Oncology Virginia Cancer Specialist, Fairfax
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/21更新 · NCT07629960A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Fairfax
- Research Site, Fredericksburg
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06692738Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
- Clinical Study Site, Blacksburg
- Clinical Study Site, Charlottesville
- Clinical Study Site, Fairfax
- 他2件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06767514ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。